Deletion of protein tyrosine phosphatase nonreceptor type 2 (PTPN2) increased the efficacy of ICIs in melanoma cells, as PTPN2 diminished the IFN-γ-mediated effects on antigen presentation and suppression of tumor growth [23, 98]. This evidence concerns the gene PTPN2 and melanoma.